TEST:

Guardant360 TissueNext™

AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene), ARID1A (AT-rich interaction domain 1A), ATM (ATM serine/threonine kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CCND1 (Cyclin D1), CCND2 (Cyclin D2), CCNE1 (Cyclin E1), CDH1 (Cadherin 1), CDK12 (Cyclin dependent kinase 12), CDK4 (Cyclin-dependent kinase 4), CDK6 (Cyclin-dependent kinase 6), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CHEK2 (Checkpoint kinase 2), CTNNB1 (Catenin (cadherin-associated protein), beta 1), DDR2 (Discoidin domain receptor 2), EGFR (Epidermal growth factor receptor), ER (Estrogen receptor), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FANCA (FA Complementation Group A), FBXW7 (F-Box And WD Repeat Domain Containing 7), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), GATA3 (GATA binding protein 3), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HNF1A (HNF1 Homeobox A), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KEAP1 (Kelch Like ECH Associated Protein 1), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MAPK1 (Mitogen-activated protein kinase 1), MAPK3 (Mitogen-Activated Protein Kinase 3), MET (MET proto-oncogene, receptor tyrosine kinase), MLH1 (MutL homolog 1), MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), MYC (V-myc avian myelocytomatosis viral oncogene homolog), MYCN (MYCN Proto-Oncogene BHLH Transcription Factor), NF1 (Neurofibromin 1), NFE2L2 (Nuclear Factor, Erythroid 2 Like 2), NOTCH1 (Notch 1), NPM1 (Nucleophosmin 1), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PALB2 (Partner and localizer of BRCA2), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PMS2 (PMS1 protein homolog 2), PTEN (Phosphatase and tensin homolog), PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), RAD51D (RAD51 paralog D), RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase), RB1 (RB Transcriptional Corepressor 1), RET (Ret Proto-Oncogene), RHEB (Ras Homolog, MTORC1 Binding), RHOA (Ras homolog family member A), RIT1 (Ras Like Without CAAX 1), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), SMAD4 (SMAD family member 4), SMO (Smoothened Frizzled Class Receptor), STK11 (Serine/threonine kinase 11), TERT (Telomerase Reverse Transcriptase), TP53 (Tumor protein P53), TSC1 (TSC complex subunit 1), VHL (von Hippel-Lindau tumor suppressor), mTOR (Mechanistic target of rapamycin kinase)